Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6.

Authors

Mark Bustoros^{1

2}, Efstathios Kastritis³, Romanos Sklavenitis-Pistofidis^{1

2}, Chia-Jen Liu^{1

2}, Kalvis Hornburg^{1

2}, Nikolaos Kanellias³, Geon Kim², David Liu², Maria Gavriatopoulou³, Catherine R Marinac^{1

4}, Maria Roussou³, Magdalini Migkou³, Kimberly Noonan^{1

2}, Kaitlen Reyes^{1

2}, Bradley Rivotto^{1

2}, Carl Jannes Neuse^{1

2}, Dimitrios C Ziogas³, Jacob Laubach^{1

2}, Evangelos Terpos³, Kenneth C Anderson², Paul G Richardson^{1

2}, Irene M Ghobrial^{1

2}, Meletios A Dimopoulos³

Affiliations

¹ Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
⁴ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

PMID: 30773670
DOI: 10.1002/ajh.25441

No abstract available

Publication types

Clinical Trial
Letter
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biopsy
Bone Marrow / pathology*
Disease-Free Survival
Follow-Up Studies
Humans
Monoclonal Gammopathy of Undetermined Significance* / diagnosis
Monoclonal Gammopathy of Undetermined Significance* / mortality
Monoclonal Gammopathy of Undetermined Significance* / pathology
Risk Factors
Smoldering Multiple Myeloma* / diagnosis
Smoldering Multiple Myeloma* / mortality
Smoldering Multiple Myeloma* / pathology
Survival Rate

Grants and funding